ArticleEuropean radiology2026
Quantitative evaluation of myocardial fibrosis in pediatric patients with Kawasaki disease and coronary artery aneurysms by MRI-derived extracellular volume fraction.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTo quantify myocardial fibrosis in Kawasaki disease (KD) patients with coronary artery aneurysms (CAAs) by MRI-derived extracellular volume fraction (ECV). MATERIALS AND
methodsThis prospective study included KD with CAAs and healthy volunteers with cardiac MRI. The image analyses included CAA size and thrombus, late gadolinium enhancement (LGE), global and regional (basal, middle, apex) ECV values. ECV values of the control and KD subgroups were compared, and the independent predictive factors of ECV were explored.
resultsThe analysis included 49 patients with large CAAs (mean age, 5.87 ± 2.18 [SD]; 40 (81.6%) males), 40 patients with medium (n = 20) and small (n = 20) CAAs (mean age, 5.34 ± 1.96 [SD]; 33 (82.5%) males), and 20 healthy volunteers (mean age, 6.22 ± 1.77 [SD]; 15 (75.0%) males). Patients with large CAAs are more prone to thrombosis than those with medium and small CAAs (p = 0.033). The global ECV value in patients with large CAAs, medium and small CAAs, and controls has a significant difference (34.37% ± 3.33 vs 33.64% ± 3.27 vs 32.23% ± 2.68, p = 0.032, p = 0.038, p = 0.006, respectively). The regional ECV value showed the same trend. There were significant differences between patients with and without coronary thrombosis and LGE (all p < 0.050). Multivariate analysis revealed that coronary artery thrombosis and LGE were independently correlated with the global ECV.
conclusionKD patients with CAAs have diffuse myocardial fibrosis, and the degree of myocardial fibrosis is more severe in patients with large CAAs and coronary thrombosis and LGE. KEY POINTS: Question Highlights the unmet need for non-invasive fibrosis quantification in KD, as prior methods (e.g., LGE) lack sensitivity for diffuse fibrosis. Findings ECV elevation (size-dependent) in CAAs, along with thrombosis and LGE, serves as an independent predictor of ECV. Clinical relevance Emphasizes ECV's role in risk stratification and guiding therapy (e.g., thromboprophylaxis), directly linking to patient outcomes.
Indexed as
Identifiers
41247478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.